# Nuclide record lighthouse (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/lighthouse/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "lighthouse", "NCT04186819" ;
  schema:name "LIGHTHOUSE"@en ;
  schema:alternateName "18F-rhPSMA-7.3 newly diagnosed prostate cancer trial"@en ;
  schema:description "A PET scan using a PSMA-targeting tracer (later approved as Posluma) was tested in men newly diagnosed with high-risk prostate cancer to see how well it spots cancer that has already spread to lymph nodes or elsewhere in the body before surgery."@en ;
  schema:url <https://nuclide.cc/trials/lighthouse/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/37414702/>, <https://clinicaltrials.gov/study/NCT04186819>, <https://www.itnonline.com/content/blue-earth-diagnostics-announces-efficacy-and-safety-results-phase-3-lighthouse-trial> ;
  nuclide:status "completed" ;
  nuclide:tag "diagnostic trial", "prostate cancer", "staging" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/drugs/flotufolastat/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/indications/prostate-high-risk/>, <https://nuclide.cc/companies/blue-earth-diagnostics/>, <https://nuclide.cc/trials/spotlight/>, <https://nuclide.cc/isotopes/f-18/> .